Population Pharmacokinetics of Primaquine in the Korean Population.
CYP2D6
carboxy-primaquine
malaria
pharmacokinetics
population pharmacokinetics
primaquine
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
29
03
2021
revised:
28
04
2021
accepted:
30
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
While primaquine has long been used for malaria treatment, treatment failure is common. This study aims to develop a population pharmacokinetic model of primaquine and its metabolite, carboxyprimaquine, and examine factors influencing pharmacokinetic variability. The data was obtained from a clinical study in 24 Korean subjects randomly assigned to normal and obese groups. The participants received primaquine 15 mg daily for 4 days and blood samples were collected at day 4. Pharmacokinetic modeling was performed with NONMEM and using simulations; the influences of doses and covariates on drug exposure were examined. A minimal physiology-based pharmacokinetic model connected with a liver compartment comprehensively described the data, with CYP450 mediated clearance being positively correlated with the body weight and CYP2D6 activity score (
Identifiants
pubmed: 34063671
pii: pharmaceutics13050652
doi: 10.3390/pharmaceutics13050652
pmc: PMC8147617
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Centers for Disease Control and Prevention, South Korea
ID : 2016-E54004-00
Références
Br Med J. 1980 Jan 19;280(6208):153-4
pubmed: 6766771
Malar J. 2015 Dec 01;14:478
pubmed: 26620122
Br J Clin Pharmacol. 2004 Aug;58(2):119-33
pubmed: 15255794
Gastroenterology. 1981 Jul;81(1):159-73
pubmed: 7016658
Am J Trop Med Hyg. 2000 Mar;62(3):393-5
pubmed: 11037784
Exp Toxicol Pathol. 1999 Jul;51(4-5):299-303
pubmed: 10445386
Bull World Health Organ. 1981;59(3):407-12
pubmed: 6976848
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28289025
Malar J. 2014 Apr 14;13:141
pubmed: 24731238
Malar J. 2012 Aug 02;11:259
pubmed: 22856549
Clin Pharmacol Ther. 2008 Feb;83(2):234-42
pubmed: 17971818
Rev Soc Bras Med Trop. 2010 Nov-Dec;43(6):749-50
pubmed: 21181040
Pathog Glob Health. 2020 Oct;114(7):388-392
pubmed: 32705964
Drug Metab Dispos. 2015 Apr;43(4):571-7
pubmed: 25637634
Arch Pharm Res. 2004 May;27(5):576-80
pubmed: 15202566
Korean J Parasitol. 2016 Dec;54(6):733-742
pubmed: 28095658
J Obes Metab Syndr. 2019 Mar;28(1):40-45
pubmed: 31089578
Malar Res Treat. 2014;2014:347018
pubmed: 25295216
Br J Clin Pharmacol. 1984 Apr;17(4):441-6
pubmed: 6721990
Eur J Med Chem. 2009 Mar;44(3):937-53
pubmed: 18930565
Clin Pharmacokinet. 2009;48(12):761-804
pubmed: 19902987
Antimicrob Agents Chemother. 2014 Jun;58(6):3354-9
pubmed: 24687509
JAMA Netw Open. 2018 Aug 3;1(4):e181449
pubmed: 30646129
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4610-9
pubmed: 27185794
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):139-46
pubmed: 23797843
Clin Infect Dis. 2004 Nov 1;39(9):1336-45
pubmed: 15494911
Malar J. 2016 Apr 19;15:224
pubmed: 27093859
Pharmacol Ther. 2016 May;161:1-10
pubmed: 27016470
N Engl J Med. 2013 Oct 3;369(14):1381-2
pubmed: 24088113
Curr Drug Metab. 2010 Mar;11(3):276-82
pubmed: 21171195
Liver Transpl. 2004 Jun;10(6):779-83
pubmed: 15162473
Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152
pubmed: 25693791
BMC Med. 2016 Oct 27;14(1):171
pubmed: 27784313
Korean J Parasitol. 2018 Dec;56(6):531-543
pubmed: 30630273
Eur J Clin Pharmacol. 1986;31(2):205-10
pubmed: 3542534
Clin Pharmacokinet. 2009;48(11):689-723
pubmed: 19817501